Risk Evaluation and Mitigation Strategies (REMS): Educating the Prescriber

Author： Nicholson Susan C.  

Publisher： Adis International

ISSN： 0114-5916

Source： Drug Safety, Vol.35, Iss.2, 2012-02, pp. : 91-104

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Risk Evaluation and Mitigation Strategies: Implications for US Pharmacists

By  

JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol. 41, Iss. 1, 2011-03 ,pp. : 5-7

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pharmaceutical industry perspective on risk evaluation and mitigation strategies: manufacturer take heed

By Nicholson Susan   Peterson Janet   Yektashenas Behin  

Expert Opinion on Drug Safety, Vol. 11, Iss. 2, 2012-03 ,pp. : 299-314

Informa Healthcare

Access to resources Recommend Favorite

US Food and Drug Administration's Risk Evaluation and Mitigation Strategy for Extended-Release and Long-Acting Opioids: Pros and Cons, and a European Perspective

By Mercadante Sebastiano  

Drugs, Vol. 72, Iss. 18, 2012-12 ,pp. : 2327-2332

Adis International

Access to resources Recommend Favorite

Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity

By Jensen Brian C   McLeod Howard L  

Pharmacogenomics, Vol. 14, Iss. 2, 2013-01 ,pp. : 205-213

Future Medicine

Access to resources Recommend Favorite

US FDA requires boxed warning and REMS for metoclopramide

By  

Reactions Weekly, Vol. 1, Iss. 1242, 2009-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite